Company intelligence / Profile preview

Discure Technologies

Ownership: Private
Development stage: Preclinical

Overview

Discure Technologies is conducting First-in-Human clinical trials of its minimally invasive, implantable bioelectronic device ("Discure System") in Canada and Italy. Preliminary results have shown a favorable safety profile and efficacy in treating disc degeneration. The company has received Breakthrough Device Designation from the FDA and was accepted into the FDA's Total Product Life Cycle Advisory Program (TAP), which is expected to expedite regulatory review and market access for its therapy targeting degenerative disc disease[3][8].

Therapeutic areas: RheumatologyNeurology
Modalities: DeviceBioelectronic device
Industry: Therapeutic Medical Devices

Partnerships

Multiple top-tier healthcare providers in the USA Fortune 50 healthcare companyUS hospital networks participating as investors/partners

Beyond the preview

Go deeper on Discure Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Discure Technologies.

Explore the full profile